Relay doubles the bar, outpacing Novartis with a 60% response in rare disease

By /

Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval.

Scroll to Top